Glaxosmithkline Pharmaceuticals Limited · NSE:GLAXO

Glaxosmithkline Pharmaceuticals — Q3 FY25 Earnings Presentation

8 slides from Glaxosmithkline Pharmaceuticals's earnings presentation, Feb 14, 2025

  1. Slide 1: GlaxoSmithKline Pharmaceuticals Limited

    GlaxoSmithKline Pharmaceuticals Limited 14th February, 2025 gsk.com

  2. Slide 2: Highlights: Celebrating a Century of Trust in India and the Launch of Chapter 2

    Highlights: Celebrating a Century of Trust in India and the Launch of Chapter 2 Iconic bell-ringing ceremony at BSE Mumbai on November 12, 2024 Unveiled Customized My Stamp and Special Cover to commemorate the 100th anniversary of GSK in India 2

  3. Slide 3: Key brands of General Medicines and Pediatric Vaccines deliver competitive external performance in Q3

    Key brands of General Medicines and Pediatric Vaccines deliver competitive external performance in Q3 2100+ STORY OF UNITING SCIENCE, ENHANCED ACCESS AND LEADERSHIP General Medicines: Majority key brands Severe asthma patients STRATEGIC RESOURCING AND ONE GSK APPROACH growing at par with market bene

  4. Slide 4: Continued efforts for Shingles awareness

    Continued efforts for Shingles awareness Win with HCPs Educate Consumers Create Vaccinators Drive Awareness 29% ~10K# All New Campaign ft. AB Partnership with KBC Shingles Monthly Avg In core 50+ patient cohort. All-new campaign ft. AB 3 audience questions on Shingles. Awareness Rx Reflection drivin

  5. Slide 5: Committed to India in our second century of operations

    Committed to India in our second century of operations… Bringing together science, technology and talent to deliver impact #AheadTogether 5

  6. Slide 6: Oct-Dec'24 (Q3 FY25): Financial Highlights

    Oct-Dec’24 (Q3 FY25): Financial Highlights Revenue EBITDA PAT ₹946cr ₹290cr (before exceptional) Growth +18% Growth +33% ₹229cr Margin: 30.7% Growth+37% Margin: 24%  Strong performance across General Medicine PAT +350 bps (YoY) flagship brands led by Augmentin, Ceftum, T- EBITDA margin +370 bps (Yo

  7. Slide 7: Apr-Dec'24 (YTD FY25): Financial Highlights

    Apr-Dec’24 (YTD FY25): Financial Highlights Revenue EBITDA PAT ₹2757cr ₹839cr (before exceptional) Growth +10% Growth +30% ₹655cr Margin: 30.4% Growth+31% Margin: 24% Revenue growth +10% EBITDA margin +450 bps (YoY) PAT +380 bps (YoY)  General Medicine key Pharma brands volume  PAT stepped up due

  8. Slide 8: gsk.com

    gsk.com

GlaxoSmithKline Pharmaceuticals — Q3 FY25 Earnings Presentation on 6ix